CN117180387B - Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof - Google Patents
Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof Download PDFInfo
- Publication number
- CN117180387B CN117180387B CN202311338686.0A CN202311338686A CN117180387B CN 117180387 B CN117180387 B CN 117180387B CN 202311338686 A CN202311338686 A CN 202311338686A CN 117180387 B CN117180387 B CN 117180387B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- facial paralysis
- wind
- phlegm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 62
- 208000026435 phlegm Diseases 0.000 title claims abstract description 62
- 208000004929 Facial Paralysis Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 20
- 241000255789 Bombyx mori Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 241000489492 Arisaema Species 0.000 claims abstract description 18
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 210000000941 bile Anatomy 0.000 claims abstract description 18
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 17
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 17
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 17
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 17
- 241000239226 Scorpiones Species 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 235000011477 liquorice Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 21
- 238000009835 boiling Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 13
- 210000000256 facial nerve Anatomy 0.000 abstract description 11
- 210000005036 nerve Anatomy 0.000 abstract description 10
- 208000006373 Bell palsy Diseases 0.000 abstract description 4
- 206010021143 Hypoxia Diseases 0.000 abstract description 3
- 206010029174 Nerve compression Diseases 0.000 abstract description 3
- 208000028867 ischemia Diseases 0.000 abstract description 3
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 60
- 230000000694 effects Effects 0.000 description 45
- 238000011282 treatment Methods 0.000 description 38
- 229940079593 drug Drugs 0.000 description 25
- 208000002193 Pain Diseases 0.000 description 22
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 206010010904 Convulsion Diseases 0.000 description 11
- 230000036461 convulsion Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 208000005392 Spasm Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 6
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 244000164480 Curcuma aromatica Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- 235000003398 Curcuma aromatica Nutrition 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001481692 Mesobuthus martensii Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- -1 hypnotic Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- TXJTZIIDMZBTEB-UHFFFAOYSA-N (3alpha,11alpha)-3,11,23-Trihydroxy-20(29)-lupen-28-oic acid Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CC(O)C3C21C TXJTZIIDMZBTEB-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- UNSYYNCAOZOYOA-UHFFFAOYSA-N 2'-ethylspiro[4,5-dihydro-2-benzofuran-3,1'-cyclopropane]-1-one Chemical compound CCC1CC11C(CCC=C2)=C2C(=O)O1 UNSYYNCAOZOYOA-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000229179 Ledebouriella Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229930185199 Sapogenol Natural products 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 208000016334 muscle symptom Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for treating wind-phlegm obstruction type peripheral facial paralysis and a preparation method thereof, wherein the composition is prepared from the following raw materials in parts by weight: 90-140 parts of stiff silkworm, 40-80 parts of scorpion, 90-140 parts of arisaema cum bile, 40-80 parts of ligusticum wallichii, 60-100 parts of radix sileris, 90-140 parts of radix curcumae, 100-150 parts of poria cocos, 120-180 parts of tuber fleeceflower stem, 90-140 parts of polygala tenuifolia, 90-140 parts of astragalus membranaceus, 90-140 parts of dried orange peel and 30-60 parts of liquorice. The composition provided by the invention can be used for treating facial nerve ischemia and anoxia caused by wind-phlegm obstruction of collaterals type peripheral facial paralysis, and nerve paralysis caused by facial nerve compression, and recovering nerve functions.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition for treating wind-phlegm obstruction type peripheral facial paralysis and a preparation method thereof.
Background
Facial paralysis, commonly called facial distortion, refers to acute non-suppurative facial neuritis in the mastoid of the neck, and is a clinical manifestation of peripheral facial paralysis, also called Bell's paralysis or idiopathic facial paralysis, which is one of the common and frequently-occurring clinical diseases. The incidence rate is 20/10 ten thousand-42.5/10 ten thousand, and the incidence rate is 258/10 ten thousand. There are many methods of clinical treatment. If the treatment is improper, the lifelong facial paralysis is often left, the face appearance is affected, and the pain is brought to patients and families.
The pathogenesis of peripheral facial paralysis is complex, the traditional Chinese medicine considers that the peripheral facial paralysis belongs to a meridian muscle symptom disease, from the aspect of human body structure, the meridian muscles of hands and feet of a human body are gathered on the face, the meridian muscles circulate in the superficial of the face so as to be easy to be invaded by exogenous evil, the patient is influenced by the invasion of exogenous evil, the vital qi is insufficient, the meridian qi cannot normally run, so that qi and blood blockage is caused, the body face loses nutrition supply, and the functional disorder of the muscles and the bones is caused; meanwhile, peripheral facial paralysis can also be caused by wind paralysis and blood obstruction, venation blockage and the like. Peripheral facial paralysis is mainly caused by wind-cold syndrome, and among wind-cold syndromes, deficiency of both healthy energy and qi deficiency are mainly caused.
The incidence rate of peripheral facial paralysis is high, and the peripheral facial paralysis can be divided into four types from the perspective of traditional Chinese medicine, namely: for the treatment of peripheral facial paralysis, it is indicated for cold syndrome. The wind-heat attack phenotype is mainly indicated for wind-dispelling and heat-clearing. For the treatment of internal stagnation of phlegm, it is mainly used for dispelling pathogenic wind and resolving phlegm. Wind-phlegm obstructing collaterals, which is mainly indicated for the treatment of eliminating phlegm, dredging collaterals, invigorating qi and nourishing blood. The patient can perform addition and subtraction treatment based on the medicine treatment.
The conventional method for treating peripheral facial paralysis mainly comprises western medicines, and the method can improve symptoms of patients, but has poor long-term curative effect and poor treatment prognosis. In recent years, the traditional Chinese medicine is widely used in the treatment of peripheral facial paralysis, has ideal effect, and can improve the recovery condition and the quality of life of patients. However, the traditional Chinese medicine for treating peripheral facial paralysis has different curative effects and poor pertinence, and the development of a safe and effective Chinese medicine preparation with simple preparation process and strong pertinence is needed.
Disclosure of Invention
In order to solve the technical problems, the first object of the present invention is to provide a composition for treating wind-phlegm obstruction type peripheral facial paralysis, and the second object is to provide a preparation method thereof, which can be used for treating facial nerve ischemia and hypoxia caused by wind-phlegm obstruction type peripheral facial paralysis, and nerve paralysis caused by facial nerve compression, and has the advantages of obvious effect, safety and reliability.
In order to achieve the first object, the technical scheme of the invention is as follows: the composition for treating wind-phlegm obstruction type peripheral facial paralysis is characterized by being prepared from the following raw materials in parts by weight: 90-140 parts of stiff silkworm, 40-80 parts of scorpion, 90-140 parts of arisaema cum bile, 40-80 parts of ligusticum wallichii, 60-100 parts of radix sileris, 90-140 parts of radix curcumae, 100-150 parts of poria cocos, 120-180 parts of tuber fleeceflower stem, 90-140 parts of polygala tenuifolia, 90-140 parts of astragalus membranaceus, 90-140 parts of dried orange peel and 30-60 parts of liquorice.
Preferably, the material is prepared from the following raw materials in parts by weight: 100 parts of stiff silkworm, 60 parts of scorpion, 100 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 70 parts of radix sileris, 100 parts of radix curcumae, 110 parts of poria cocos, 140 parts of tuber fleeceflower stem, 110 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 100 parts of dried orange peel and 40 parts of liquorice.
Preferably, the material is prepared from the following raw materials in parts by weight: 110 parts of stiff silkworm, 70 parts of scorpion, 110 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 160 parts of tuber fleeceflower stem, 120 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 110 parts of dried orange peel and 50 parts of liquorice.
Preferably, the material is prepared from the following raw materials in parts by weight: 120 parts of stiff silkworm, 70 parts of scorpion, 130 parts of arisaema cum bile, 60 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 170 parts of tuber fleeceflower stem, 130 parts of polygala tenuifolia, 130 parts of astragalus membranaceus, 120 parts of dried orange peel and 50 parts of liquorice.
The second object of the present invention is achieved by: a preparation method of a composition for treating wind-phlegm obstruction type peripheral facial paralysis is characterized by comprising the following steps: adding water into the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating.
In the scheme, the method comprises the following steps: the water adding amount for the first decoction is 6-10 times of the total dosage, and the water adding amount for the second decoction is 3-4 times of the total dosage. The above amounts are all by mass.
In the scheme, the method comprises the following steps: concentrating to one third of the twice added water.
In the scheme, the method comprises the following steps: and adding medicinal or edible carrier or adjuvant, and making into oral liquid preparation or oral solid preparation. Adding carrier or adjuvant after concentrating, and making into oral liquid or oral solid preparation
In the scheme, the method comprises the following steps: the oral solid preparation is tablet, capsule, granule.
The invention selects the medicines for combination, and combines the medicines to generate synergistic effect on the efficacy of each medicine, thereby effectively treating the wind-phlegm obstruction type peripheral facial paralysis. All the medicinal materials are received in the 2020 edition of Chinese pharmacopoeia.
The invention has the advantages of low-cost and easily obtained raw materials, simple preparation method, low cost and good effect, is easy to take, can be used for treating facial nerve ischemia and hypoxia caused by wind-phlegm obstruction type peripheral facial paralysis and nerve paralysis caused by facial nerve compression, and is an innovation of medicines for treating wind-phlegm obstruction type peripheral facial paralysis.
The dosage and the course of treatment of the traditional Chinese medicine composition can be properly adjusted according to the dosage form, the age of a patient and the degree of severity of the disease, and the traditional Chinese medicine composition can be continuously used for a plurality of courses of treatment with 2 months as one course of treatment.
The traditional Chinese medicine composition for treating wind-phlegm obstruction type peripheral facial paralysis has the following characteristics of the individual medicines in 12 raw material medicines, namely the main medicines with the characteristics of meridian tropism, efficacy, main treatment symptoms, medical records and pharmacological actions:
The stiff silkworm is a whole worm body of Vuillant stiff row infected with beauveria bassiana Beauveria bassiana (Bals.) of the family Fabricius, the nature is salty, pungent and flat, and the stiff silkworm has the effects of dispelling wind and relieving spasm, and resolving phlegm and resolving masses, and is clinically used for treating tangible masses such as nodules, sore throat, scrofula, wind sore urticaria and the like. In Shennong Ben Cao Jing: "mainly infantile convulsion and night cry, remove three worms, kill black, make the complexion good, and male yin sore. "Ben Cao gang mu": "wind-phlegm-dispelling tuberculosis, scrofula, headache, wind-worm toothache, skin wind-sore, erysipelas itching, … … all sores, furuncle wind-hemorrhoids. Modern pharmacological research shows that batryticated silkworm mainly contains protein, fat, various amino acids and microelements such as iron, zinc, copper, manganese and chromium. The white powder on the body surface of the silkworm contains ammonium oxalate. Has sedative, hypnotic, anticonvulsant, anticoagulant, antitumor, and blood glucose lowering effects.
The scorpion is a dried body of Buthus martensii Karsch Buthus MARTENSII KARSCH of Buthus martensii Karsch, has the effects of calming endogenous wind and relieving spasm, eliminating toxin and resolving hard mass, and dredging collaterals and relieving pain, and is mainly used for treating infantile convulsion, convulsion and spasm, askew stroke mouth, hemiplegia, tetanus, wind-damp obstinate arthralgia, migraine, pyocutaneous disease and scrofula. In "Yuhua Yao Jie": "penetrate tendons and penetrate joints, remove dampness and wind. Modern pharmacological research shows that scorpion contains scorpion venom, enzyme and other active components. Has antiepileptic, anticonvulsant, analgesic, antitumor, antithrombotic, blood pressure lowering, and antibacterial effects.
The arisaema cum bile is prepared by processing arisaema tuber fine powder and cow, sheep or pig bile (Chinese pharmacopoeia), or is prepared by fermenting arisaema tuber fine powder and cow, sheep or pig bile, has bitter and cold taste, is cool, enters lung, liver and spleen meridians, has the effects of clearing fire and resolving phlegm, relieving convulsion and arresting epilepsy, and is used for treating apoplexy, convulsion and epilepsy, phlegm fire and asthma cough, dizziness and the like. In "Bencaozheng": "treating infantile acute convulsions, excessive phlegm and excessive fire obstructing upper energizer, dyspnea and dysphoria, thirst and distention and fullness". "Ben Cao Hui Yan": for infantile convulsions, convulsions of limbs, internal heat due to deficiency of qi and heat Yu Sheng phlegm. "Dannan xing has the actions of clearing heat and resolving phlegm, dannan xing is bitter and cool, bitter can dry dampness and resolve phlegm, and cold can clear heat, and can be used for treating symptoms such as phlegm-fire cough, dizziness, apoplexy, phlegm stagnation, senile mental retardation, postpartum severe palpitation, phlegm-fire insomnia and the like.
The ligusticum wallichii is rhizome of ligusticum wallichii Ligusticum chuanxiong Hort belonging to the family Umbelliferae, has pungent and warm nature, enters into liver and gall meridians, has the effects of activating blood circulation, promoting qi circulation, dispelling wind and relieving pain, and is used for irregular menstruation, amenorrhea, dysmenorrhea, abdominal pain, thorny chest and hypochondrium pain, traumatic injury, headache, rheumatalgia and the like. In the book of changes: "mainly apoplexy involving brain headache, cold arthralgia, spasm of tendons, gold wound, and blood obstruction of women without son". "Ming Yi Bie Lu (Ming Yi Bie Lu)": the medicine is effective in removing cold in brain, removing wind from upstream face, removing tears, excessive nasal discharge and saliva, neglecting, such as drunk, cold qi, hard pain in heart and abdomen, aversion to middle-jiao, acute swelling and pain, hypochondriac pain, and warm middle-jiao and internal cold. "drug theory": for treating weakness of waist and feet, hemiplegia, primary dystonia, and cold pain in abdomen. Modern pharmacological research shows that chuanxiong rhizome contains chuanxiongzine, ligustilide, neoligustilide, etc. Has effects in relieving myocardial ischemia, improving blood rheology, relieving cerebral ischemia, relieving fever, and tranquilizing mind.
The radix sileris is root of a plant Saposhnikovia divaricata (Trucz.) of Fangfeng genus of Umbelliferae, has pungent and sweet nature and slightly warm nature, enters meridians of bladder, lung, spleen and liver, has the effects of sweating, eliminating phlegm, dispelling wind, relieving exterior syndrome and easing pain, and is used for treating symptoms such as cold, headache, joint pain of the whole body, neuralgia and the like. In the book of changes: the main wind is dizzy and painful, aversion to wind, pathogenic wind, blindness, general wind, arthralgia and restlessness. "Ming Yi Bie Lu (Ming Yi Bie Lu)": hypochondriac pain, hypochondriac wind-head and face removal, limb spasm, internal spasm of the sore with mammary gland. "Ben Cao Jing Shu": the Chinese medicinal composition is suitable for wind prevention and treatment, and can be used for ascending and dispersing, so that the Chinese medicinal composition is mainly used for treating dizziness and pain, aversion to wind evil, bone and joint pain arthralgia, hypochondriac pain and hypochondriac pain on the face of the head. Modern pharmacological studies have shown that ledebouriella root contains components such as sapogenol, cimicifuga rhizome glycoside, etc. Has effects in relieving fever, tranquilizing, relieving pain, relieving convulsion, and resisting allergy.
The Curcuma aromatica is dried root tuber of Curcuma aromatica Curcuma rcenyujin Y.H.Chen et C.Ling, curcuma longa L, curcuma zedoaria Curcumakwangsiensis S.G.Lee et C.F.Liang or Curcuma zedoaria Curcuma phaeocaulis Val. Drug Property theory describes: for female with blood, qi and heart pain, cold and accumulation, wen Cuma is taken. "Ben Cao gang mu": for postpartum septicemia, heart-flushing, and crazy, it is indicated for heart failure and vesania. Modern pharmacological research shows that curcuma root contains curcumin, demethoxycurcumin, curcumene and other components. Has effects in protecting liver, reducing blood viscosity, and inhibiting platelet aggregation.
The Poria cocos disclosed by the invention is sclerotium of Polyporaceae fungus Poria cocos (Schw) Wolf, has sweet, light and flat taste, is nontoxic, and has the effects of excreting dampness and promoting diuresis, tonifying spleen and stomach and kidney, soothing nerves and promoting fluid production and the like, and is used for quenching thirst, promoting urination, dehumidifying and tonifying dryness, and regulating middle warmer and tonifying qi. In the book of changes: "chest and hypochondrium adverse qi, frightening frightening evil, palpitation, pain in heart and lower extremities, dysphoria with smothery sensation, fullness and dysphoria, cough and adverse qi, mouth Jiao Shegan, and urination. Is taken for a long time, and has the effects of tranquilizing mind, allaying hunger and prolonging life. Modern pharmacological research shows that poria cocos has the effects of regulating immunity, promoting urination, resolving stone, protecting liver, resisting leukemia, resisting tumor, resisting fatigue, resisting aging and the like.
The tuber fleeceflower stem is the rattan stem or rattan stem with leaves of polygonum multiflorum Polygonum multi florum Thunb of the polygonaceae, has sweet nature and taste, is calm, enters heart and liver channels, has the effects of nourishing heart and soothing nerves, dredging collaterals and dispelling wind and the like, and is used for insomnia, fatigue, hyperhidrosis, blood deficiency body pain, carbuncle, scrofula, wind sore and scabies and the like. In "materia medica regeneration": bitter taste, warm nature and no toxicity. Modern pharmacological research shows that tuber fleeceflower stem contains emodin, chrysophanol, luteolin-5-O-xyloside and other components. Has effects in reducing blood lipid, preventing and treating atherosclerosis, tranquilizing mind, and hypnotizing.
The polygala tenuifolia is the dried root of polygala tenuifolia Polygala tenuifolia Willd, which is a polygala tenuifolia family plant, has bitter, pungent and warm nature, enters heart, kidney and lung channels, has the effects of soothing nerves, improving intelligence, eliminating phlegm and detumescence, and is used for insomnia and dreaminess, amnesia and palpitation, tranquility, expectoration, unsmooth phlegm, pyocutaneous disease swelling and toxin, breast swelling and the like caused by heart-kidney imbalance. In the book of changes: in the cough and adverse flow of qi, the main cough is deficient in tonifying, removing pathogenic factors, inducing nine orifices, benefiting wisdom, improving hearing and hearing, not forgetting, and strengthening the strength. "Ming Yi Bie Lu (Ming Yi Bie Lu)": "centering Qi, stopping palpitation, replenishing essence, removing diaphragmatic Qi of heart and skin heat and yellow complexion". "drug theory": "treating heart-mind and strengthening spring, strengthening yang and channel. The main dream evil. Modern pharmacological research shows that polygala tenuifolia contains polygala tenuifolia sapogenin A, polygala tenuifolia sapogenin B, polygala tenuifolia tut-tut ketone III and other components. Has sedative and hypnotic effects, and is effective in relieving convulsion, eliminating phlegm, and resisting aging.
The astragalus membranaceus is the root of astragalus membranaceus Astragalus membranaceus (Fisch.) bge. Var. Mongholicus (bge.) Hsiao or astragalus membranaceus Astragalus membranaceus (Fisch.) bge. Of Leguminosae, has sweet taste and slight temperature, is used for restoring menstrual flow, and has the effects of tonifying qi, consolidating exterior, promoting urination, strengthening heart, reducing blood pressure, resisting bacteria, expelling toxin, promoting pus, promoting granulation and the like, and is used for treating spontaneous perspiration due to exterior deficiency, internal injury due to qi deficiency, diarrhea due to spleen deficiency, edema, carbuncle and the like. Modern pharmacological studies show that astragalus contains astragalus saponin I, II, III, IV and other components. Has effects in enhancing immunity, promoting hematopoiesis, delaying aging, lowering blood sugar, lowering blood pressure, and reducing blood lipid.
The tangerine peel is ripe peel of rutaceae plant tangerine Citrus reticulata Blanco and cultivated varieties thereof. The dried orange peel has warm, pungent and bitter taste and is good for spleen, stomach and lung meridians, and has the effects of regulating qi, strengthening spleen, regulating middle warmer, drying dampness and resolving phlegm. Can be used for treating abdominal distention, pain, and dyspepsia due to qi stagnation of spleen and stomach. Chest distress, abdominal distention, anorexia and loose stool due to damp-turbidity obstruction. Cough and asthma due to phlegm-dampness obstructing the lung. Can be used for treating fullness in chest and epigastrium, anorexia, vomiting and diarrhea, cough with excessive phlegm, etc. In Ben Cao gang mu: the' its qi-regulating and dampness-drying actions are taken until the time of its hundred, and the same tonic and laxative are used for tonifying, the same ascending and descending are used for descending. Spleen is the mother of primordial qi, lung is the requirement of qi-taking, so orange peel is the requirement of qi-dividing of two meridians, but it is also accompanied by the ascending and descending of reinforcing and reducing. "in daily herbal: "can dispel energy and purge, warm energy and tonify, can dispel diaphragmatic qi, resolve phlegm and saliva, harmonize spleen and relieve cough, and treat five stranguria. Modern pharmacological research shows that orange peel contains hesperidin, nobiletin, neohesperidin and other components. Has effects in regulating gastrointestinal motility, relieving allergy, relieving asthma, resisting tumor, eliminating phlegm, and reducing serum cholesterol.
The liquorice provided by the invention is dry roots and rhizomes of liquorice Glycyrrhiza uralensis Fisch, liquorice Glycyrrhiza inflata Bat or liquorice Glycyrrhiza glabra L which are leguminous plants, has sweet and flat taste, is used for heart, lung, spleen and stomach channels, has the effects of invigorating spleen and replenishing qi, nourishing cough and moistening lung, relieving urgency and detoxification, harmonizing medicines and the like, and is used for sore throat, carbuncle and sore, gastrointestinal ulcer, drug toxicity relieving, food poisoning and the like. In Ming Yi Bie Lu: warming middle-jiao and descending qi, relieving restlessness and shortness of breath, injuring viscera and relieving cough, quenching thirst, dredging channels and collaterals, li Xieqi and relieving hundred medicine toxins. "drug theory": cold pain in the main abdomen, treating convulsive epilepsy and removing abdominal distention and fullness; tonify five viscera; preparing various drug toxins; nourishing kidney-qi and relieving internal injury, causing yin (not) flaccidity; housewives experience lower back pain; deficiency and excessive heat; and is used in addition. Modern pharmacological studies show that licorice contains glycyrrhizin, glycyrrhizic acid, glycyrrhizin and other components. Has effects in resisting peptic ulcer, inhibiting bacteria, removing toxic substances, and inhibiting contraction of uterine smooth muscle.
The exogenous cause of this disease is wind. Wind is a long disease and is easy to get other diseases. "Ling Shu-Jing Jin" cloud: the patient can lead to acute cheek movement when the cheek tendon of … … is cold, and can lead to slow and non-superior tendon movement when the cheek tendon is hot. The cold and heat evil is considered to easily invade the facial meridians as a disease. The cause of this disease is deficiency. "Su-Wen-Ji-fei-Bing Lun (plain question and evaluation of fever theory of diseases)": the pathogenic qi is deficient due to the accumulation of pathogenic factors. The pathogenesis of wind-phlegm obstruction of collaterals and remote mouth is that pathogenic wind-cold invades the face channels and collaterals, mainly relates to the yangming channels and collaterals. "Ling Shu-Jing Jin" cloud: the yang of the foot, the rapid movement of the hand, the rapid movement of the tendons and eyes, the acute movement of the canthus, and the inability to stroke. The treatment mainly comprises dispelling wind and resolving phlegm, and tonifying qi and nourishing blood.
The stiff silkworm has the effects of dispelling wind and dredging collaterals, reducing phlegm, and the scorpion has the effects of calming endogenous wind and relieving spasm, and dredging collaterals and relieving pain, and is a monarch drug. Arisaema cum bile has the functions of clearing heat and resolving phlegm, calming endogenous wind and arresting convulsion. Ligusticum wallichii has the effects of promoting blood circulation and activating qi-flowing, dispelling wind and relieving pain, and radix sileris has the effects of dispelling wind and eliminating dampness and relieving pain and spasm, and radix curcumae has the effects of promoting blood circulation and relieving pain and activating qi-flowing as ministerial drugs. Poria cocos has the effects of promoting diuresis and removing dampness, tuber fleeceflower stem has the effects of dispelling wind and dredging collaterals, radix polygalae has the effects of eliminating phlegm and detumescence, radix astragali has the effects of promoting diuresis and detumescence, promoting stagnancy and relieving arthralgia, and pericarpium citri reticulatae has the effects of regulating qi, eliminating dampness and resolving phlegm as adjuvant drugs. Licorice root, radix Glycyrrhizae regulates the action of other drugs and acts as a guiding drug. Because wind-damp herbs are pungent and dry, they are used to nourish blood, activate blood and remove meridian obstruction, so they are in line with the meaning of treating wind first and blood going out of wind and restrict the dryness of wind-damp herbs. The whole formula has the effects of dispelling wind and resolving phlegm, and also has the effects of replenishing blood, promoting blood circulation and nourishing yin, so as to treat facial paralysis caused by wind-phlegm obstruction of collaterals. Clinically, the treatment can be modified according to the actual conditions.
The invention has complementary advantages of all the medicines, and the medicines are combined to fully play the synergistic effect of all the medicines, so that the product can be used for treating peripheral facial paralysis caused by obstruction of wind-phlegm by multiple ways under the combined action of multiple active ingredients.
Detailed Description
The invention is further described below with reference to examples.
Example 1
The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 100 parts of stiff silkworm, 60 parts of scorpion, 100 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 70 parts of radix sileris, 100 parts of radix curcumae, 110 parts of poria cocos, 140 parts of tuber fleeceflower stem, 110 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 100 parts of dried orange peel and 40 parts of liquorice. Wherein, all the raw materials are added with water for 10 times, soaked for 15-25 min at 18-25 ℃, then boiled with strong fire, decocted with slow fire for 20-30 min, and filtered to obtain filtrate for standby; adding water into the filter residue for 3 times, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating to one third of the water content. Adding appropriate amount of adjuvants, mixing, granulating with boiling granulating equipment, and tabletting.
Example 2
The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 110 parts of stiff silkworm, 70 parts of scorpion, 110 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 160 parts of tuber fleeceflower stem, 120 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 110 parts of dried orange peel and 50 parts of liquorice. Adding water 6 times of all the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue for 4 times, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating to one third of the water content. Adding appropriate amount of adjuvant, mixing, granulating with boiling granulating equipment, and making into capsule.
Example 3
The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 120 parts of stiff silkworm, 70 parts of scorpion, 130 parts of arisaema cum bile, 60 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 170 parts of tuber fleeceflower stem, 130 parts of polygala tenuifolia, 130 parts of astragalus membranaceus, 120 parts of dried orange peel and 50 parts of liquorice. Adding 8 times of water into all the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue for 3 times, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating to one third of the water content. The boiling granulation equipment is adopted, and a proper amount of auxiliary materials are added to prepare the granules.
Example 4
The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 90 parts of stiff silkworm, 40 parts of scorpion, 90 parts of arisaema cum bile, 40 parts of ligusticum wallichii, 60 parts of radix sileris, 90 parts of radix curcumae, 90 parts of poria cocos, 140 parts of tuber fleeceflower stem, 90 parts of polygala tenuifolia, 90 parts of astragalus membranaceus, 90 parts of dried orange peel and 30 parts of liquorice. Adding water 10 times of all the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue for 3 times, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating to one third of the water content. Granulating with boiling granulating equipment, and tabletting with tablet press.
Example 5
The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 140 parts of stiff silkworm, 80 parts of scorpion, 140 parts of arisaema cum bile, 80 parts of ligusticum wallichii, 80 parts of radix sileris, 100 parts of radix curcumae, 150 parts of poria cocos, 180 parts of tuber fleeceflower stem, 120 parts of polygala tenuifolia, 100 parts of astragalus membranaceus, 140 parts of dried orange peel and 60 parts of liquorice. Adding water 10 times of all the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue for 3 times, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating to one third of the water content. Granulating with boiling granulating equipment, and tabletting with tablet press.
The beneficial effects of the invention are further illustrated by the following test examples:
clinical efficacy evaluation of wind-phlegm obstruction of collaterals type peripheral facial paralysis patient
84 Patients with wind-phlegm obstruction type peripheral facial paralysis are selected, the ages are 20-56, and the disease course is 2-7 days. The treatment method comprises randomly dividing into 4 groups, namely an example 1 group, an example 2 group, an example 3 group and a western medicine control group, wherein 21 cases of each group are respectively provided with 11 men and 10 women, and the cases of each group have no significant difference in symptoms, gender, age, disease course and the like.
Western diagnostic criteria
Meets the diagnosis standard of idiopathic facial palsy in neurology, namely, facial paralysis, loss of forehead lines, facial distortion and air leakage during whistle.
Diagnostic criteria for traditional Chinese medicine
Meets the diagnosis standard of the apoplexy phlegm obstruction collaterals type remote mouth disease in the diagnosis curative effect standard of the traditional Chinese medicine syndrome, and has facial distortion and abnormal feeling.
Inclusion criteria
Meets the diagnostic criteria; unilateral onset; age 18-70 years; the course of the disease is 2 to 7 days; intolerance to acupuncture and moxibustion; voluntarily receives the present treatment regimen.
Exclusion criteria
Central facial paralysis; patients with severe gravity center, brain, kidney, etc.; mental patients; gestational and lactating patients; allergic patients.
Therapeutic method
Examples 1-3 Chinese medicinal composition treatment groups: each group of 21 patients, 63 patients, were respectively decocted with water 3 times a day to obtain 300mL decoction, which was taken 3 times a day with the Chinese medicinal composition described in examples 1-3 of the present invention. Treatment 14d.
Western medicine control group: in 21 patients, prednisone acetate tablet (5 mg/tablet) is taken in the morning, 30mg daily, and 5mg is decreased daily after 5d until the administration is stopped; mecobalamin tablets (0.5 mg/tablet) are orally taken, 0.5mg daily, 3 times daily; thrombus (250 mg/branch) for injection was added to 200mL of a 0.9% sodium chloride injection by intravenous drip 1 time a day. Treatment 14d.
Efficacy evaluation criteria
(1) Facial nerve function. The degree of illness before and after treatment was compared using House-Brackmann facial nerve function (H-B) scale. (2) clinical efficacy. Two groups of clinical efficacy were observed with reference to the H-B scale. ① heals: the clinical symptoms and physical signs completely disappear, no facial distortion exists during actions such as laughing and the like, the expression is recovered to be normal, and the nerve function of the H-B surface is graded to be grade I; ② shows effect: clinical symptoms and physical signs largely disappear, the expression is basically normal when the patient is at rest, but the expression action still has slight skew when the emotion is excited, and the H-B facial nerve function is graded to be II grade; ③ is effective: the clinical symptoms and the physical sign part disappear, the symptoms are obviously askew when the emotion is excited, and the H-B surface nerve function is graded to be III grade; ④ null: the clinical symptoms and physical signs are not improved, and the H-B surface nerve function is graded to IV grade or above.
Total effective rate= (cure + effect + effective) number of cases/total number of cases x 100%.
Results
1. Clinical efficacy comparison: the total effective rates of the traditional Chinese medicine compositions in the embodiment 1, the embodiment 2 and the embodiment 3 for treating the wind-phlegm obstruction type facial paralysis are respectively 90.5%, 95.2% and 90.5%, the total effective rates of the positive control western medicine treatment are respectively 71.4%, the curative effect of the traditional Chinese medicine composition groups in the embodiment 1-3 is obviously superior to that of the western medicine control group, and the difference has statistical significance (P is less than 0.05), and the table is shown in the table 1.
2. Facial nerve function improvement comparison: there was no statistical difference in the H-B grade comparisons of the groups prior to treatment. After treatment, the patients (grade of H-B surface nerve function is classified into grade I) cured by the traditional Chinese medicine composition treatment groups of the embodiment 1, the embodiment 2 and the embodiment 3 are respectively 7, 8 and 6, the patients (grade of H-B surface nerve function is classified into grade II) cured by the traditional Chinese medicine composition treatment groups of the embodiment 1, the embodiment 2 and the embodiment 3 are respectively 9, 10 and 11, the patients cured by the positive control western medicine treatment groups and the patients cured by the effective treatment groups are only 3 and 6, the improvement condition of the nerve function after the treatment of the traditional Chinese medicine composition treatment groups of the embodiment 1 to 3 is obviously superior to that of the positive control western medicine treatment, and the difference has statistical significance (P is less than 0.05), and the statistical significance is shown in the table 1.
3. Toxic and side effects: the traditional Chinese medicine composition treatment groups and the western medicine control treatment group in examples 1-3 have no obvious adverse reaction and obvious toxic and side effects before and after the treatment of the cases.
Surface.1 treatment of peripheral facial paralysis patient before and after treatment
Note that: compared with western medicine control treatment group, * P is less than 0.05
The clinical research results of the traditional Chinese medicine composition for treating wind-phlegm obstruction type peripheral facial paralysis show that the traditional Chinese medicine composition for treating wind-phlegm obstruction type peripheral facial paralysis has reasonable formula compatibility, has the effects of eliminating phlegm and dredging collaterals, can remarkably improve the treatment effect on wind-phlegm obstruction type peripheral facial paralysis and improve the facial nerve function of patients, and has good safety tolerance.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. The composition for treating wind-phlegm obstruction type peripheral facial paralysis is characterized by being prepared from the following raw materials in parts by weight: 90-140 parts of stiff silkworm, 40-80 parts of scorpion, 90-140 parts of arisaema cum bile, 40-80 parts of ligusticum wallichii, 60-100 parts of radix sileris, 90-140 parts of radix curcumae, 100-150 parts of poria cocos, 120-180 parts of tuber fleeceflower stem, 90-140 parts of polygala tenuifolia, 90-140 parts of astragalus membranaceus, 90-140 parts of dried orange peel and 30-60 parts of liquorice;
The preparation method comprises the following steps: adding water into the raw materials, soaking for 15-25 min at 18-25 ℃, boiling with strong fire, decocting with slow fire for 20-30 min, and filtering to obtain filtrate for later use; adding water into the filter residue, boiling with strong fire, decocting with slow fire for 10-15 min, filtering, discarding the filter residue to obtain filtrate, mixing the two filtrates, and concentrating.
2. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 100 parts of stiff silkworm, 60 parts of scorpion, 100 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 70 parts of radix sileris, 100 parts of radix curcumae, 110 parts of poria cocos, 140 parts of tuber fleeceflower stem, 110 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 100 parts of dried orange peel and 40 parts of liquorice.
3. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 110 parts of stiff silkworm, 70 parts of scorpion, 110 parts of arisaema cum bile, 50 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 160 parts of tuber fleeceflower stem, 120 parts of polygala tenuifolia, 120 parts of astragalus membranaceus, 110 parts of dried orange peel and 50 parts of liquorice.
4. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 120 parts of stiff silkworm, 70 parts of scorpion, 130 parts of arisaema cum bile, 60 parts of ligusticum wallichii, 80 parts of radix sileris, 120 parts of radix curcumae, 130 parts of poria cocos, 170 parts of tuber fleeceflower stem, 130 parts of polygala tenuifolia, 130 parts of astragalus membranaceus, 120 parts of dried orange peel and 50 parts of liquorice.
5. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 4, wherein: the water adding amount for the first decoction is 6-10 times of the total dosage, and the water adding amount for the second decoction is 3-4 times of the total dosage.
6. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 5, wherein: concentrating to one third of the twice added water.
7. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 6, wherein: and adding medicinal or edible carrier or adjuvant, and making into oral liquid preparation or oral solid preparation.
8. The composition for treating wind-phlegm obstruction type peripheral facial paralysis according to claim 7, wherein: the oral solid preparation is tablet, capsule, granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311338686.0A CN117180387B (en) | 2023-10-17 | 2023-10-17 | Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311338686.0A CN117180387B (en) | 2023-10-17 | 2023-10-17 | Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117180387A CN117180387A (en) | 2023-12-08 |
CN117180387B true CN117180387B (en) | 2024-06-14 |
Family
ID=88994404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311338686.0A Active CN117180387B (en) | 2023-10-17 | 2023-10-17 | Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117180387B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751453A (en) * | 2013-12-20 | 2014-04-30 | 霍山县中医院 | Traditional Chinese medicinal composition for treating peripheral facial paralysis |
-
2023
- 2023-10-17 CN CN202311338686.0A patent/CN117180387B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751453A (en) * | 2013-12-20 | 2014-04-30 | 霍山县中医院 | Traditional Chinese medicinal composition for treating peripheral facial paralysis |
Also Published As
Publication number | Publication date |
---|---|
CN117180387A (en) | 2023-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111214566A (en) | Epidemic prevention traditional Chinese medicine composition and preparation method and application thereof | |
CN103169923B (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method of traditional Chinese medicine composition | |
CN104383296B (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
CN105456897A (en) | Traditional Chinese medicine composition containing argy wormwood leaf for treating spleen deficiency gasterasthenia type chronic gastritis | |
CN105434856A (en) | Medicine for treating alopecia caused by liver-kidney deficiency and qi-blood deficiency | |
CN104001045A (en) | Drug for treating dog pneumonia and preparation method thereof | |
CN117180387B (en) | Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof | |
CN104984027A (en) | Chinese materia medica preparation for treating myelodysplastic syndrome and preparation method thereof | |
CN105596551A (en) | Traditional Chinese medicine composition having asthenopia relieving function and preparation method thereof | |
CN104906430A (en) | Traditional Chinese medicine preparation for treating xerophthalmia and preparation method thereof | |
CN103211964A (en) | Chinese medicament for treating cough | |
CN107823293A (en) | Treat Yao nationality medicine external pulvis of canker sore and preparation method thereof | |
CN102579871B (en) | Traditional Chinese medical composition for treatment of chronic rhinitis and preparation method thereof | |
CN102293941B (en) | Chinese medicinal composition for treating diabetes mellitus | |
CN104435685A (en) | Medicine for treating xerophthalmia and preparation method thereof | |
CN110934974A (en) | Traditional Chinese medicine composition for treating lung cancer, traditional Chinese medicine preparation and preparation method thereof | |
CN104623612A (en) | Drug for promoting blood circulation to remove blood stasis and treating acute mastitis and preparation method thereof | |
CN110624060A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea and preparation method thereof | |
CN104740405B (en) | A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage | |
CN110123896B (en) | Pharmaceutical composition for adjuvant treatment of tumor and preparation method thereof | |
CN108524651B (en) | Traditional Chinese medicine composition for treating tracheitis | |
CN107753584B (en) | Chinese ephedra anti-allergic traditional Chinese medicine composition and preparation method thereof | |
CN107854651B (en) | Chinese medicinal preparation for treating apoplexy, hyperlipemia and blood hyperviscosity and production method thereof | |
CN106421411A (en) | Stomach tonifying functional beverage | |
CN105169348A (en) | Traditional Chinese medicine preparation for promoting pancreas incision drainage postoperative rehabilitation and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |